Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis
A Phase II Multicenter, Randomized, Double Blind Study to Assess the Safety, Tolerability and Efficacy of Two Concentrations of ZEP-3Na Topical Cream (0.1% and 1%) Compared to Vehicle-control in Subjects With Mild to Moderate Atopic Dermatitis With an Open Label Extension of up to 2 Weeks Treatment With ZEP-3Na Topical Cream 1%
Sponsor: Shulov Innovate for Science Ltd. 2012
This PHASE2 trial investigates Atopic Dermatitis and is currently ongoing. Shulov Innovate for Science Ltd. 2012 leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Nov 2025 — Present [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Mar 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Apr 2022 — Mar 2023 [monthly]
Recruiting PHASE2
-
Apr 2021 — Apr 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Nov 2020 [monthly]
Recruiting PHASE2
First recorded
Dec 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shulov Innovate for Science Ltd. 2012
For direct contact, visit the study record on ClinicalTrials.gov .